I think you're missing the point. Well, my point at least.I...

I think you're missing the point. Well, my point at least.

I don't think anyone's saying Frewena shouldn't have been first cab off the rank but with the looming option expiry (and a potential $6.5m up for grabs), the seeming (to me) lethargy of the board/management to generate some action/news (whatever) to try to get the options in the money and exercised, is to me, surprising and disappointing.

To be polite.

Of course, if the assays come out in the next few weeks with something that gets the price back into the mid teens or better, great.

But that outcome seems less likely every day that passes?